Pharmacological subgroup
L01E – PROTEINKINASE-INHIBITOREN
151Decisions
270Patient groups
Added benefit by patient group
- Major5
- Considerable29
- Minor27
- Non-quantifiable19
- Not proven188
- Lesser benefit2
Subgroups
- L01EA BCR-ABL-Tyrosinkinase-Inhibitoren 7 decisions
- L01EB Epidermaler Wachstumsfaktor-Rezeptor (EGFR)-Tyrosinkinase-Inhibitoren 10 decisions
- L01EC BRAF-Serin-Threoninkinase-Inhibitoren 9 decisions
- L01ED Anaplastische Lymphomkinase (ALK)-Inhibitoren 12 decisions
- L01EE Mitogen-aktivierte Proteinkinase (MEK)-Inhibitoren 11 decisions
- L01EF Cyclin-abhängige Kinasen (CDK)-Inhibitoren 14 decisions
- L01EH Humaner epidermaler Wachstumsfaktor-Rezeptor 2 (HER2)-Tyrosinkinase-Inhibitoren 2 decisions
- L01EJ Janus-assoziierte Kinase (JAK)-Inhibitoren 5 decisions
- L01EK Vaskulärer endothelialer Wachstumsfaktor-Rezeptor (VEGFR)-Tyrosinkinase-Inhibitoren 3 decisions
- L01EL Bruton-Tyrosinkinase (BTK)-Inhibitoren 21 decisions
- L01EM Phosphatidylinositol-3-kinase (Pi3K)-Inhibitoren 7 decisions
- L01EN Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren 3 decisions
- L01EP Zellulär-mesenchymal-epithelialer Transitionsfaktor(c-MET)kinase-Inhibitoren 2 decisions
- L01EX Andere Proteinkinase-Inhibitoren 45 decisions
Decisions, newest first
- 2026-08-20VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-08-06KoselugoSelumetinibNon-quantifiable
- 2026-06-18RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2026-05-21ScemblixAsciminibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-05-07KoselugoSelumetinibMinor
- 2026-05-07KoselugoSelumetinibNon-quantifiable
- 2026-05-07AyvakytAvapritinibMinor
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-04-16OmjjaraMomelotinibNot proven: 2 of 2 patient groups
- 2026-04-16RomvimzaVimseltinibConsiderable
- 2026-03-19EzmeklyMirdametinibNon-quantifiable
- 2026-02-19ItovebiInavolisibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven: 2 of 2 patient groups
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-11-20RetsevmoSelpercatinibMajor
- 2025-11-20ScemblixAsciminibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-10-16AugtyroRepotrectinibNot proven: 3 of 3 patient groups
- 2025-10-02JaypircaPirtobrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2025-08-21InrebicFedratinibNon-quantifiable
- 2025-08-07JaypircaPirtobrutinibNot proven
- 2025-08-07OfevNintedanibNot proven
- 2025-08-07OfevNintedanibNot proven
- 2025-07-17LazcluzeLazertinibMinor
- 2025-07-03TagrissoOsimertinibNot proven: 2 of 2 patient groups
- 2025-06-18BalversaErdafitinibNot proven: 3 of 3 patient groups
- 2025-06-05KisqaliRibociclibNot proven: 3 of 3 patient groups
- 2025-04-03TruqapCapivasertibConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2025-03-20BraftoviEncorafenibNot proven: 3 of 3 patient groups
- 2025-03-20MektoviBinimetinibNot proven: 3 of 3 patient groups
- 2025-02-06TagrissoOsimertinibNot proven
- 2025-01-16AlecensaAlectinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-01-16FruzaqlaFruquintinibMinor
- 2024-12-19TagrissoOsimertinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-11-22LytgobiFutibatinibNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2024-10-17SpexotrasTrametinibConsiderable: 1 of 3 patient groupsNon-quantifiable: 2 of 3 patient groups
- 2024-10-17FinleeDabrafenibConsiderable: 1 of 3 patient groupsNon-quantifiable: 2 of 3 patient groups
- 2024-08-01VanflytaQuizartinibNot proven
- 2024-06-06BrukinsaZanubrutinibNot proven
- 2024-05-02RydaptMidostaurinNot proven
- 2024-05-02RydaptMidostaurinNot proven
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-07-20ImbruvicaIbrutinibNot proven: 2 of 2 patient groups
- 2023-06-15VerzeniosAbemaciclibMinor
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2023-06-15BrukinsaZanubrutinibNot proven
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-03-16ScemblixAsciminibMinor
- 2023-02-02TabrectaCapmatinibNot proven: 3 of 3 patient groups
- 2022-12-15IbrancePalbociclibNot proven
- 2022-12-01Cabometyx CabozantinibNot proven
- 2022-10-20VerzeniosAbemaciclibNot proven
- 2022-09-01LorviquaLorlatinibNot proven
- 2022-09-01TepmetkoTepotinibNot proven: 3 of 3 patient groups
- 2022-07-21CopiktraDuvelisibNot proven
- 2022-07-21CopiktraDuvelisibNot proven: 4 of 4 patient groups
- 2022-07-07LenvimaLenvatinibConsiderable
- 2022-07-07KisplyxLenvatinibNot proven: 2 of 2 patient groups
- 2022-06-16QinlockRipretinibMajor
- 2022-06-16BrukinsaZanubrutinibNot proven
- 2022-06-16GavretoPralsetinibNot proven: 5 of 5 patient groups
- 2022-05-19VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-03-18CaprelsaVandetanibNot proven
- 2021-12-16CometriqCabozantinibNon-quantifiable
- 2021-11-19BosulifBosutinibNot proven
- 2021-10-21Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2021-10-07PemazyrePemigatinibNon-quantifiable
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-09-02RetsevmoSelpercatinibNot proven: 3 of 3 patient groups
- 2021-09-02TukysaTucatinibConsiderable
- 2021-09-02InrebicFedratinibNon-quantifiable
- 2021-08-05CalquenceAcalabrutinibConsiderable: 1 of 5 patient groupsMinor: 1 of 5 patient groupsNot proven: 3 of 5 patient groups
- 2021-07-01KisplyxLenvatinibNot proven
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-04-01ImbruvicaIbrutinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-18PiqrayAlpelisibNot proven: 3 of 5 patient groupsLesser benefit: 2 of 5 patient groups
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-04OfevNintedanibMinor
- 2021-02-04OfevNintedanibNot proven
- 2020-12-17BraftoviEncorafenibConsiderable
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2020-10-15AlunbrigBrigatinibConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2020-09-03VerzeniosAbemaciclibNot proven
- 2020-08-20KisqaliRibociclibMinor: 2 of 2 patient groups
- 2020-08-20KisqaliRibociclibMinor
- 2020-05-14NerlynxNeratinibMinor
- 2020-05-14XospataGilteritinibConsiderable
- 2020-04-02VitrakviLarotrectinibNot proven
- 2020-02-20ImbruvicaIbrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2020-02-20ImbruvicaIbrutinibNot proven
- 2019-11-22LorviquaLorlatinibNot proven: 2 of 2 patient groups
- 2019-10-17VizimproDacomitinibNot proven: 2 of 2 patient groups
- 2019-10-17OfevNintedanibConsiderable
- 2019-08-15LenvimaLenvatinibNot proven
- 2019-07-04AlunbrigBrigatinibNot proven
- 2019-07-04KisqaliRibociclibNot proven: 5 of 5 patient groups
- 2019-06-06Cabometyx CabozantinibMinor
- 2019-05-02VerzeniosAbemaciclibNot proven
- 2019-05-02VerzeniosAbemaciclibNot proven: 3 of 3 patient groups
- 2019-03-22IbrancePalbociclibNot proven: 2 of 2 patient groups
- 2019-03-22BraftoviEncorafenibNot proven: 2 of 2 patient groups
- 2019-03-22MektoviBinimetinibNot proven: 2 of 2 patient groups
- 2019-03-22MekinistTrametinibConsiderable
- 2019-03-22TafinlarDabrafenibConsiderable
- 2019-03-22LenvimaLenvatinibNot proven: 2 of 2 patient groups
- 2019-02-21BosulifBosutinibNot proven: 2 of 2 patient groups
- 2019-01-17TagrissoOsimertinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-12-06Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2018-06-21AlecensaAlectinibNon-quantifiable
- 2018-04-19FotivdaTivozanibNot proven: 3 of 3 patient groups
- 2018-04-05Cabometyx CabozantinibMinor
- 2018-02-01ZykadiaCeritinibNot proven
- 2017-10-19TafinlarDabrafenibNot proven: 3 of 3 patient groups
- 2017-10-19MekinistTrametinibNot proven: 3 of 3 patient groups
- 2017-10-19TagrissoOsimertinibConsiderable
- 2017-10-19AlecensaAlectinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-09-21InlytaAxitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-07-06CaprelsaVandetanibNon-quantifiable
- 2017-05-18IbrancePalbociclibNot proven
- 2017-03-16ImbruvicaIbrutinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-03-16XalkoriCrizotinibNot proven: 3 of 3 patient groups
- 2017-03-16ZykadiaCeritinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-03-16ZydeligIdelalisibNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2016-12-15ImbruvicaIbrutinibNot proven: 3 of 3 patient groups
- 2016-12-15XalkoriCrizotinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20GiotrifAfatinibNot proven: 2 of 2 patient groups
- 2016-09-15ZydeligIdelalisibNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-09-15TagrissoOsimertinibNot proven: 4 of 4 patient groups
- 2016-07-21ImbruvicaIbrutinibConsiderable: 1 of 6 patient groupsNon-quantifiable: 2 of 6 patient groupsNot proven: 3 of 6 patient groups
- 2016-06-16XalkoriCrizotinibConsiderable
- 2016-06-02CotellicCobimetinibConsiderable
- 2016-03-17StivargaRegorafenibNot proven
- 2016-03-17MekinistTrametinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-03-17TafinlarDabrafenibConsiderable
- 2015-11-05GiotrifAfatinibMajor: 1 of 5 patient groupsNot proven: 4 of 5 patient groups
- 2015-10-15JakaviRuxolitinibConsiderable
- 2015-06-18VargatefNintedanibMinor
- 2015-03-19ZydeligIdelalisibNot proven
- 2015-02-19StivargaRegorafenibNot proven
- 2014-11-06JakaviRuxolitinibConsiderable
- 2014-04-03TafinlarDabrafenibNot proven
- 2014-03-06ZelborafVemurafenibConsiderable
Data status: 2026-10-29